RESUMEN
BACKGROUND: The optimal clinical management of patients following ingestion of potentially caustic lesions is still undetermined. In particular, the indication for early upper GI endoscopy in this context remains unclear. PURPOSE: To draft recommendations regarding the use of early upper GI endoscopy following hospital admissions of patients after ingestion of potentially caustic agents. METHODS: For this purpose, a retrospective cohort study of patients treated for ingestion of potentially caustic substances during a 13 year-period at the university hospital of Berne was performed. RESULTS: In total, 61 patients with acute ingestion of potentially caustic substances were identified. Overall mortality was 5â%. 11/61 patients had to be admitted to the intensive care unit. Most ingestions were performed in suicidal intention (62â%). In 53â% of these patients, a combined ingestion of several substances occurred. In 33â% of patients, an early upper GI endoscopy was performed within 24 hours after ingestion. The degree of burn depended upon the hazard potential of the respective substance. In patients with ingestion of low risk substances, upper GI endoscopy was only performed when additional risk factors were present. CONCLUSION: Based upon the results of the present study, ingestion of potentially caustic agents requires an individualized strategy whether or not to perform early endoscopy.
Asunto(s)
Quemaduras Químicas/cirugía , Cáusticos/envenenamiento , Toma de Decisiones Clínicas , Endoscopía del Sistema Digestivo/mortalidad , Endoscopía del Sistema Digestivo/estadística & datos numéricos , Estenosis Esofágica/inducido químicamente , Estenosis Esofágica/mortalidad , Quemaduras Químicas/mortalidad , Quemaduras Químicas/patología , Estenosis Esofágica/patología , Femenino , Alemania/epidemiología , Humanos , Estudios Longitudinales , Masculino , Selección de Paciente , Complicaciones Posoperatorias/mortalidad , Complicaciones Posoperatorias/patología , Complicaciones Posoperatorias/prevención & control , Prevalencia , Pronóstico , Derivación y Consulta , Estudios Retrospectivos , Factores de Riesgo , Tasa de Supervivencia , Centros de Atención Terciaria , Resultado del TratamientoRESUMEN
The current recommendations on indications, technical performance, and interpretation of diagnostic techniques for oesophageal reflux update the German recommandations about 24 hour pH measurement of 2003. The recommendations encompass conventional pH measurement, wireless pH measurement, pH and impedance measurements, and bilirubin measurement (duodenogastro-oesophageal reflux).
Asunto(s)
Bilirrubina/sangre , Determinación de la Acidez Gástrica , Gastroenterología/normas , Reflujo Gastroesofágico/diagnóstico , Concentración de Iones de Hidrógeno , Pletismografía de Impedancia/normas , Guías de Práctica Clínica como Asunto , Alemania , HumanosRESUMEN
Strictures are a frequent complication of eosinophilic esophagitis. The efficacy and safety of topical corticosteroids and of dilation of eosinophilic esophagitis-associated strictures have not yet been thoroughly clarified. We present a retrospective analysis of 10 adult patients with eosinophilic esophagitis who had symptomatic esophageal stenosis that was unresponsive to topical corticosteroids, and who were treated using bougienage. Eight patients had one single stricture, one patient had two, and another had three strictures; mean stricture length was 2.1 cm (range 1 - 6 cm). Bougienage led to prompt symptom relief. Apart from transient postprocedural odynophagia, no severe complications occurred. During the follow-up (mean 6 months; range 2 - 11 months), all patients enjoyed sustained treatment response.
Asunto(s)
Cateterismo/métodos , Eosinofilia/complicaciones , Estenosis Esofágica/terapia , Esofagitis/complicaciones , Administración Tópica , Adolescente , Corticoesteroides/uso terapéutico , Adulto , Niño , Preescolar , Estudios de Cohortes , Estenosis Esofágica/etiología , Esofagoscopía/métodos , Femenino , Estudios de Seguimiento , Humanos , Masculino , Estudios Retrospectivos , Medición de Riesgo , Índice de Severidad de la Enfermedad , Insuficiencia del TratamientoRESUMEN
Chronic and/or recurrent abdominal symptoms which are (a) focused on the upper abdomen and (b) can not be explained by structural or biochemical abnormalities are characteristic features for functional dyspepsia. Although significant progress in the understanding of the underlying pathophysiological mechanisms has been achieved in the past years, the crucial question how to treat this functional syndrome is still only partially answered. The current treatment options are mainly symptom-oriented and do not always fulfil all prerequisites of modern evidence-based medicine. However; new therapeutic approaches and inter-disciplinary treatment strategies seem to represent first promising steps towards a solution for this problem.
Asunto(s)
Dispepsia/fisiopatología , Vaciamiento Gástrico/fisiología , Terapia Combinada , Dispepsia/diagnóstico , Dispepsia/tratamiento farmacológico , Fármacos Gastrointestinales/uso terapéutico , Humanos , Psicoterapia , Psicotrópicos/uso terapéutico , Trastornos Somatomorfos/diagnóstico , Trastornos Somatomorfos/fisiopatología , Trastornos Somatomorfos/terapiaRESUMEN
The acute upper gastrointestinal bleeding continues to represent one of the most frequent gastrointestinal emergencies both in hospital and out-patient settings. While the underlying etiology is widespread, the leading causes for such bleeding events are gastro-duodenal ulcers and esophageal or gastric varices. Given the potential life-threatening character of the bleeding, the first step in treating such a patient is the assessment of the severity of the bleeding based upon clinical and laboratory parameters. This translates into the time point of performing an endoscopy of the upper gastrointestinal tract. The role of gastro-esophago-duodenoscopy is defined by its dual function for the diagnosis of the exact origin of the bleeding and the therapy of the bleeding during the same examination. Drug administration has to accompany this endoscopic intervention. Effective acid suppression is in the focus of conservative treatment. In case of varices, additional medication has to be given to lower the portovenous pressure. Following persistent bleeding after endoscopic intervention, radiological and surgical treatment options have to be discussed in time.
Asunto(s)
Cuidados Críticos/métodos , Hemorragia Gastrointestinal/diagnóstico , Hemorragia Gastrointestinal/terapia , Enfermedad Aguda , Enfermedades Duodenales/diagnóstico , Enfermedades Duodenales/terapia , Enfermedades del Esófago/diagnóstico , Enfermedades del Esófago/terapia , Alemania , Humanos , Guías de Práctica Clínica como Asunto , Pautas de la Práctica en Medicina , Gastropatías/diagnóstico , Gastropatías/terapiaRESUMEN
BACKGROUND: Increased prevalence of functional gastrointestinal disorders in women and perimenstrually accentuated symptoms imply that sexual hormones play a crucial role in the pathogenesis of such syndromes. The aim of this study was to analyze the selective effect of estrogen on visceral sensitivity in gonadectomized female and male Lewis rats with or without prior treatment with butyrate enemas. METHODS: Following ovariectomy (OVX) or orchiectomy (ORX) estradiol pellets (E2-P) or sham pellets (Sham-P) were implanted. After treatment with butyrate (BUT) or saline (NaCl) enemas, colorectal distensions (CRD) were performed and the visceromotor reflex (VMR) to CRD was measured by electromyography. KEY RESULTS: Gender did not influence VMR to CRD in gonadectomized animals. VMR in E2-P animals compared to Sham-P animals was increased (635 ± 32 µVs vs 470 ± 39 µVs; p = 0.002). Overall, instillation of butyrate enemas did not influence VMR to CRD. A comparison of CRD clusters showed that butyrate enemas in the E2-P animals resulted in a significant sensitization in both OVX and ORX animals. In female rats, sensitization was also caused by estrogen substitution alone. CONCLUSION & INFERENCES: In our animal model, estrogen is a strong factor for an increase in visceral sensory function. Surprisingly, the treatment with butyrate alone did not evoke a general rise in VMR to CRD. Rats treated with butyrate enemas and under selective estrogen substitution developed visceral sensitization during the series of CRDs.
Asunto(s)
Modelos Animales de Enfermedad , Estrógenos/administración & dosificación , Dolor Visceral/tratamiento farmacológico , Dolor Visceral/fisiopatología , Animales , Colon , Implantes de Medicamentos/administración & dosificación , Femenino , Hiperalgesia/tratamiento farmacológico , Hiperalgesia/fisiopatología , Masculino , Orquiectomía , Ovariectomía , Ratas , Ratas Endogámicas Lew , Factores Sexuales , Resultado del TratamientoRESUMEN
AIM: To compare the efficacy of simethicone with placebo and the prokinetic cisapride in patients with functional dyspepsia. METHODS: One hundred and eighty-five patients with functional dyspepsia were randomized and treated in a double-dummy technique with simethicone (105 mg t.d.s.), cisapride (10 mg t.d.s.) or placebo (t.d.s.). The primary outcome measure was the O'Brien global measure of the patients' rating of 10 upper gastrointestinal symptoms (graded as absent = 0, moderate = 1, severe = 2 or very severe = 3). Outcome measures were assessed at baseline and after 2, 4 and 8 weeks of treatment (intention-to-treat). RESULTS: At 2, 4 and 8 weeks, treatment with simethicone and cisapride yielded significantly (all P values < 0.0001) better improvement of symptoms compared to placebo. Simethicone was significantly better than cisapride after 2 weeks (P = 0.0007), but the differences were not statistically significant after 4 and 8 weeks. Patients treated with simethicone judged the efficacy of their treatment as very good in 46% of cases, compared to 15% and 16% receiving cisapride and placebo, respectively. CONCLUSIONS: Simethicone and cisapride were significantly better than placebo for symptom control in patients with functional dyspepsia after 2, 4 and 8 weeks of treatment. Simethicone was also superior to the prokinetic cisapride in the first 2 weeks of treatment.
Asunto(s)
Cisaprida/uso terapéutico , Dispepsia/tratamiento farmacológico , Fármacos Gastrointestinales/uso terapéutico , Simeticona/uso terapéutico , Adulto , Anciano , Método Doble Ciego , Dispepsia/microbiología , Femenino , Indicadores de Salud , Infecciones por Helicobacter/complicaciones , Helicobacter pylori , Humanos , Masculino , Persona de Mediana Edad , Cooperación del Paciente , Satisfacción del Paciente , Resultado del TratamientoRESUMEN
AIM: To compare the efficacy of simethicone with cisapride in patients with functional (non-ulcer) dyspepsia. METHODS: After standardized diagnostic work-up and at least 6-days wash-out of medication, 177 patients with functional dyspepsia were enrolled; 173 of them (age 19-71 years) were randomized and treated using a double-dummy technique with simethicone (84 mg t.d.s.) or cisapride (10 mg t.d.s.). At baseline and after 2 and 4 weeks, the intensity of the symptoms was scored from 0 (absent) to 3 (severe) using a standardized symptom questionnaire. Efficacy of the treatment was judged by the patients as 'very good', 'good', 'moderate' or 'no effect'. RESULTS: A total of 166 patients completed the trial. After 2 and 4 weeks, 34% and 46% (respectively), of the patients treated with simethicone judged the improvement in symptoms to be excellent compared to 13% and 22% (respectively) of patients treated with cisapride (P < 0.01). After 2 weeks the difference in the improvement in the global symptom score was significantly better (Delta30.7%, P < 0.001) for simethicone than for cisapride, while this difference failed statistical significance after 4 weeks (Delta10.2%, P=0.11). CONCLUSIONS: In patients with functional dyspepsia, simethicone relieves symptoms during the first 2 weeks of treatment significantly better than cisapride.
Asunto(s)
Cisaprida/uso terapéutico , Dispepsia/tratamiento farmacológico , Fármacos Gastrointestinales/uso terapéutico , Simeticona/uso terapéutico , Cisaprida/efectos adversos , Método Doble Ciego , Dispepsia/microbiología , Femenino , Fármacos Gastrointestinales/efectos adversos , Helicobacter pylori/efectos de los fármacos , Humanos , Masculino , Persona de Mediana Edad , Cooperación del Paciente , Simeticona/efectos adversos , Factores de TiempoRESUMEN
Abstract In a number of different experimental paradigms of somatic pain, there is evidence for a vagally mediated antinociceptive system. This pathway probably involves opioid mechanisms. However, whether this pathway is activated in visceral pain or if it involves subdiaphragmatic vagal afferents is unclear. The aim of the present study was to determine whether subdiaphragmatic vagal afferents mediate antinociception in response to a visceral stimulus and whether this involves an opioid pathway. Colorectal distension was performed in fasted, conscious male Sprague-Dawley rats using a balloon catheter connected to an electronic distension device. The number of abdominal contractions (visceromotor response) in response to a tonic colorectal distension (60 mmHg for 10 min) was recorded. Experiments were performed in sham or subdiaphragmatically vagotomized, perineural vehicle- or capsaicin-treated rats (to functionally denervate vagal afferents) before and after administration of naloxone (25 mg kg(-1) bodyweight intraperitoneally). Vagotomy, capsaicin and naloxone pretreatments all significantly enhanced the visceromotor response to colorectal distension. The effect of naloxone in capsaicin-treated rats did not appear to be additive. These results suggest that activation of subdiaphragmatic afferents, which can be blocked by capsaicin, may play a role in opioid-dependent antinociceptive pathways activated by a noxious visceral stimulus.
Asunto(s)
Colon/fisiología , Diafragma/inervación , Péptidos Opioides/fisiología , Dimensión del Dolor/métodos , Recto/fisiología , Nervio Vago/fisiología , Vías Aferentes/efectos de los fármacos , Vías Aferentes/fisiología , Animales , Colon/efectos de los fármacos , Colon/inervación , Diafragma/efectos de los fármacos , Diafragma/fisiología , Motilidad Gastrointestinal/efectos de los fármacos , Motilidad Gastrointestinal/fisiología , Masculino , Naloxona/farmacología , Dimensión del Dolor/efectos de los fármacos , Dimensión del Dolor/estadística & datos numéricos , Ratas , Ratas Sprague-Dawley , Recto/efectos de los fármacos , Recto/inervación , Vagotomía/métodos , Vagotomía/estadística & datos numéricos , Nervio Vago/efectos de los fármacosRESUMEN
This study aimed to characterize the role of the neuropeptide calcitonin gene-related peptide (CGRP) in the development of mechanically induced visceral hyperalgesia. Tonic colorectal distension (CRD) was performed in fasted, conscious male Sprague-Dawley rats. The visceromotor reflex associated with noxious CRD was determined as the number of contractions during each of two consecutive tonic distensions (10 min at 60 mmHg), which were separated by a series of phasic distensions (repeated 15-s distensions to 80 mmHg at 30-s intervals). The effect of the CGRP receptor antagonist h-CGRP8-37 given intrathecally (i.t.) (0.03-3 nmol rat-1) or intravenously (i.v.) (20 microg kg-1 bodyweight [bw]) on the visceromotor response was evaluated. The dose for i.v. administration was chosen based on previous results from similar studies. In addition, the effect of a CGRP monoclonal antibody (6 mg kg-1 bw) given intravenously was evaluated. Compared to the baseline response, a significant increase in the number of abdominal contractions was observed during the second tonic distension. The i.t. application of h-CGRP8-37 dose-dependently reduced the numbers of abdominal contractions both during the first and the second tonic distension period, with a maximum effect observed at a peptide concentration of 3 nmol. Intravenous administration of h-CGRP8-37 or of the CGRP antiserum produced a small reduction of the visceromotor response induced by the second tonic distension and had no effect on colonic compliance. The development of mechanically induced colorectal hyperalgesia by repeated tonic distension involves the spinal release of CGRP, while peripheral release of CGRP plays only a minor role.
Asunto(s)
Péptido Relacionado con Gen de Calcitonina/farmacología , Colon/fisiología , Hiperalgesia/fisiopatología , Mióticos/farmacología , Fragmentos de Péptidos/farmacología , Médula Espinal/fisiología , Aferentes Viscerales/metabolismo , Enfermedad Aguda , Animales , Anticuerpos Monoclonales/farmacología , Péptido Relacionado con Gen de Calcitonina/inmunología , Antagonistas del Receptor Peptídico Relacionado con el Gen de la Calcitonina , Cateterismo , Colon/inervación , Motilidad Gastrointestinal/efectos de los fármacos , Motilidad Gastrointestinal/fisiología , Inyecciones Intravenosas , Inyecciones Espinales , Masculino , Músculo Liso/inervación , Músculo Liso/fisiología , Fragmentos de Péptidos/inmunología , Ratas , Ratas Sprague-Dawley , Receptores de Péptido Relacionado con el Gen de Calcitonina/metabolismoRESUMEN
Most patients with functional bowel disorders complain of daytime symptoms while they remain asymptomatic at night. As symptoms are associated with heightened visceral sensitivity, we hypothesized that circadian fluctuations of the visceral sensory function occur. At four different timepoints (06.00, 12.00, 18.00 and 24.00 h), colorectal distensions (CRD) were performed in fasting conscious male Lewis rats using a balloon catheter and a barostat device. The abdominal wall contractions (behavioural pain response) were assessed during colorectal distension by abdominal wall electromyography (EMG). Plasma levels for endogenous cortisol were determined simultaneously at these timepoints. EMG responses to CRD were significantly (P < 0.05) higher at midnight and in the early morning. Plasma cortisol levels peaked in the evening. In night-active Lewis rats, the behavioural pain response to noxious visceral stimulation is augmented at night and fluctuations of visceral sensitivity are accompanied by circadian changes of plasma concentrations of endogenous cortisol. We conclude that there are marked circadian fluctuations in visceral sensory functions. Thresholds are low during time periods of normal behavioural activity. These findings suggest that fluctuation of the sensory functions may be linked to the circadian variability of symptoms in patients with functional GI disorders.
Asunto(s)
Ritmo Circadiano/fisiología , Colon/fisiología , Motilidad Gastrointestinal/fisiología , Hidrocortisona/sangre , Recto/fisiología , Abdomen , Animales , Conducta Animal , Cateterismo , Electromiografía , Masculino , Estimulación Física , Ratas , Ratas Endogámicas LewRESUMEN
The aim of this study was to characterize plasma membrane pathways involved in the intracellular calcium ([Ca(2+)](i)) response of small DRG neurons to mechanical stimulation and the modulation of these pathways by kappa-opioids. [Ca(2+)](i) responses were measured by fluorescence video microscopy of Fura-2 labeled lumbosacral DRG neurons obtained from adult rats in short-term primary culture. Transient focal mechanical stimulation of the soma, or brief superfusion with 300 nM capsaicin, resulted to [Ca(2+)](i) increases which were abolished in Ca(2+)-free solution, but unaffected by lanthanum (25 microM) or tetrodotoxin (10(-6) M). 156 out of 465 neurons tested (34%) showed mechanosensitivity while 55 out of 118 neurons (47%) were capsaicin-sensitive. Ninty percent of capsaicin-sensitive neurons were mechanosensitive. Gadolinium (Gd(3+); 250 microM) and amiloride (100 microM) abolished the [Ca(2+)](i) transient in response to mechanical stimulation, but had no effect on capsaicin-induced [Ca(2+)](i) transients. The kappa-opioid agonists U50,488 and fedotozine showed a dose-dependent inhibition of mechanically stimulated [Ca(2+)](i) transients but had little effect on capsaicin-induced [Ca(2+)](i) transients. The inhibitory effect of U50,488 was abolished by the kappa-opioid antagonist nor-Binaltorphimine dihydrochloride (nor-BNI; 100 nM), and by high concentrations of naloxone (30-100 nM), but not by low concentrations of naloxone (3 nM). We conclude that mechanically induced [Ca(2+)](i) transients in small diameter DRG somas are mediated by influx of Ca(2+) through a Gd(3+)- and amiloride-sensitive plasma membrane pathway that is co-expressed with capsaicin-sensitive channels. Mechanical-, but not capsaicin-mediated, Ca(2+) transients are sensitive to kappa-opioid agonists.
Asunto(s)
3,4-Dicloro-N-metil-N-(2-(1-pirrolidinil)-ciclohexil)-bencenacetamida, (trans)-Isómero/farmacología , Compuestos de Bencilo/farmacología , Capsaicina/farmacología , Ganglios Espinales/fisiología , Neuronas/fisiología , Propilaminas/farmacología , Receptores Opioides kappa/fisiología , Amilorida/farmacología , Animales , Calcio/metabolismo , Células Cultivadas , Gadolinio/farmacología , Ganglios Espinales/citología , Técnicas In Vitro , Cinética , Masculino , Naltrexona/análogos & derivados , Naltrexona/farmacología , Neuronas/efectos de los fármacos , Estimulación Física , Ratas , Ratas Sprague-Dawley , Receptores Opioides kappa/agonistas , Receptores Opioides kappa/antagonistas & inhibidoresRESUMEN
A multimodal approach is state-of-the art for effective treatment of functional gastrointestinal disorders (FGD) like irritable bowel syndrome and functional dyspepsia. Based on the now established view that the pathogenesis of FGD is multicausal, evidence-based therapeutic options comprise education about the nature of the disorder, dietary modifications, relaxation techniques, behavioral changes, and pharmacological treatments. These therapies are variously combined depending on the severity of the FGD and the individual needs of the patient. Our overview portrays the options for the therapy of FGD and proposes that these are best provided by an interdisciplinary team of primary care physicians, gastroenterologists, and psychosomatic medicine specialists.
Asunto(s)
Dispepsia/terapia , Síndrome del Colon Irritable/terapia , Dolor Abdominal/etiología , Antidepresivos/uso terapéutico , Biorretroalimentación Psicológica , Ensayos Clínicos como Asunto , Terapia Combinada , Dispepsia/complicaciones , Dispepsia/tratamiento farmacológico , Dispepsia/psicología , Conducta Alimentaria , Predicción , Humanos , Indoles/uso terapéutico , Síndrome del Colon Irritable/complicaciones , Síndrome del Colon Irritable/tratamiento farmacológico , Metaanálisis como Asunto , Cooperación del Paciente , Probióticos/uso terapéutico , Psicoterapia , Calidad de Vida , Terapia por Relajación , Agonistas de Receptores de Serotonina/uso terapéutico , Estrés Psicológico , Encuestas y CuestionariosRESUMEN
BACKGROUND: The high prevalence of functional bowel disorders among the general population contrasts with the limited number of pharmacological treatment options for this condition. This has led to an interest for alternative therapeutic approaches. Padma Lax is an herbal laxative on the basis of Tibetan formulas. Our aim is to examine the effect of Padma Lax on visceral nociception in vivo and (B) on contractile activity of longitudinal smooth muscle of the lower gut in vitro and ex vivo. METHODS: (A) Visceral sensory function in response to colorectal distension was assessed by abdominal wall electromyography in male Wistar rats pretreated with Padma Lax. (B) Effects of Padma Lax on contractility of gut smooth muscles were studied both in vitro with superfusion of the agent and ex vivo following oral administration of the preparation. Activities were measured as area under the curve. KEY RESULTS: (A) For visceral sensitivity, no differences were observed between the Padma Lax and the control group. (B) Proximal colon muscle strips of the Padma Lax pretreated group showed significantly lower spontaneous contractility ex vivo than controls. Cholinergic procontractile stimulation was reduced in Padma Lax pretreated group and in colon strips of naive rats when Padma Lax was superfused in vitro (all P < 0.05). CONCLUSION & INFERENCES: Cholinergic mechanisms appear to be important in the modulation of rat proximal colon contractility of orally and directly applied Padma Lax. These findings help elucidate a potential mechanism of action of this herbal remedy which has undergone clinical testing in patients with constipation predominant irritable bowel syndrome.
Asunto(s)
Contracción Muscular/efectos de los fármacos , Músculo Liso/efectos de los fármacos , Dolor/tratamiento farmacológico , Fitoterapia , Extractos Vegetales/uso terapéutico , Acetilcolina/farmacología , Animales , Área Bajo la Curva , Colon/efectos de los fármacos , Colon/fisiopatología , Dilatación Patológica/fisiopatología , Electromiografía , Masculino , Músculo Liso/fisiopatología , Dolor/fisiopatología , Extractos Vegetales/farmacología , Ratas , Ratas WistarRESUMEN
Functional gastrointestinal disorders (FGD) are highly prevalent worldwide. Recent research demonstrates that complex and interacting biological and behavioral mechanisms contribute particularly to the pathogenesis of irritable bowel syndrome and functional dyspepsia. Dysregulation of the enteral, neuroenteric, visceral-autonomic, and central nervous systems are important biological contributors, whereas the psychological state of a patient may evidently modulate aspects related to biological stress reactivity and somatic perception both playing a role in the clinical manifestation of FGD. Our overview clearly shows that an interdisciplinary perspective of the pathogenesis of FGD may best serve clinicians and patients.
Asunto(s)
Enfermedades Gastrointestinales/etiología , Grupo de Atención al Paciente , Terapia Combinada , Diagnóstico Diferencial , Dispepsia/etiología , Dispepsia/terapia , Enfermedades Gastrointestinales/terapia , Síndrome del Colon Irritable/etiología , Síndrome del Colon Irritable/terapiaAsunto(s)
Aprotinina/administración & dosificación , Coagulación Sanguínea , Transfusión de Sangre Autóloga , Procedimientos Quirúrgicos Cardíacos , Fluidoterapia , Método Doble Ciego , Hemoglobinometría , Hemorragia/prevención & control , Humanos , Complicaciones Intraoperatorias/prevención & control , Tiempo de Tromboplastina Parcial , Complicaciones Posoperatorias/prevención & control , Tiempo de ProtrombinaRESUMEN
Given its high prevalence and the chronic course of disease, the Irritable Bowel Syndrome (IBS) represents an important clinical picture for general practioners. IBS is primarily characterized by chronic recurrent abdominal pain and changes in stool habits which are not explained by pathological findings in routine diagnostic procedures. The etiology of IBS seems to be multifactorial with both intrinsic and extrinsic aspects. Main pathophysiological alterations associated with IBS are changes in gastrointestinal motility and in perception and modulation of visceral pain. The therapeutic options how to treat IBS patients are primarily symptomatic. Given potential adverse effects of causally oriented treatment strategies, the latter ones are yet limited.
Asunto(s)
Síndrome del Colon Irritable/diagnóstico , Terapia Combinada , Comorbilidad , Diagnóstico Diferencial , Medicina Familiar y Comunitaria , Humanos , Síndrome del Colon Irritable/etiología , Síndrome del Colon Irritable/terapia , Calidad de VidaRESUMEN
The acute compartment syndrome describes a posttraumatic or inflammatory edema, which leads to a painful constraint of muscular movement and paresthesia. An increase in pressure in the anatomical compartment is postulated. The main symptoms include local swelling, sensory loss, local muscle weakness as well as late livid discoloration. Therapy of choice is an early fasciotomy with decompression to avoid serious complications like muscle necrosis. Here we report a 22 year old patient who postoperatively suffered from a bilateral paresis of the foot jack. Further examinations by electromyography and magnetic resonance imaging (MRI) led to the diagnosis of an acute bilateral compartment syndrome.